cervical cancer
Conditions
Interventions
test group:Concurrent chemoradiotherapy or Concurrent chemoradiotherapy combined Apatinib
control group:Concurrent chemoradiotherapy or Concurrent chemoradiotherapy
Sponsors
The People's Hosptial of Liuzhou City
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Cervical squamous cell carcinoma first diagnosed by histopathology; 2. Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB2 or above; 3. KPS score > 60; 4. The Expected lifetime =3 months; 5. No radiochemotherapy contraindications; 6. Without anti-tumor therapy; 7. Aged between 18 and 70 years old; 8. Participants volunteered to participate in this study, signed informed consent, compliance, with follow-up.
Exclusion criteria
Exclusion criteria: 1. Previously received anti-cancer treatment; 2. Being tested by other drugs; 3. Have had other malignant tumors in the past; 4. Severe complications: including hypertension that is difficult to control with drugs, myocardial infarction, severe arrhythmia, severe cerebrovascular disease, active peptic ulcer; 5. According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient or affect the patient's completion of the study; 6. Researchers consider it inappropriate to be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;OS; | — |
Countries
China
Contacts
Public ContactChanjuan He
The People's Hospital of Liuzhou City
Outcome results
None listed